Biomarin Pharmaceutical Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Good afternoon. I'm -- sorry. Good afternoon. Thanks for joining us. I'm Salveen Richter, biotechnology analyst at Goldman Sachs. We're really pleased to have BioMarin with us today, for which Jean-Jacques Bienaime, Chairman and CEO; and Brian Mueller, CFO, have joined us.
With that, J.J., I'm going to turn it over to you for introductory comments, and then we can jump to questions.
Okay. Thank you, Salveen. We appreciate the opportunity to speak with you today. So as you know, BioMarin is a fully integrated global leader in rare disease drug discovery, development, manufacturing, commercialization. Over the last few years, we've built a company designed for significant growth. Our global infrastructure incorporates a strong base business, delivering close to $2 billion of revenues annually, durable and scalable pipeline of innovative products and regulatory capabilities. And we have
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
